Acceleron Pharma (XLRN) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts XLRN Hot Sheet
Join SI Premium – FREE
Acceleron Pharma (NASDAQ: XLRN) reported Q2 EPS of ($0.63), $0.01 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $3.7 million versus the consensus estimate of $3.8 million.
– MEDALIST and BELIEVE Phase 3 trials met all primary and key secondary endpoints –
– ACE-083 Part 2 of the Phase 2 trials in facioscapulohumeral muscular dystrophy and Charcot-Marie-Tooth disease are underway –
– PULSAR Phase 2 trial initiated with sotatercept in pulmonary arterial hypertension –
For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
- New Horizon Aircraft (HOVR) Misses Q1 EPS by 6c
- Mangoceuticals closes $500K offering at 74% premium to recent price
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
